Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Garmo

Showing results (11-20 of 275) with videos related to

Pageof 28
Sort By:
The Journal of Urology|June 22, 2016
Cancer Specific Mortality in Men Diagnosed with Prostate Cancer before Age 50 Years: A Nationwide Population Based StudyAndreas Thorstenson, Hans Garmo, Jan Adolfsson, et al.
Cancer Causes & Control : CCC|June 26, 2015
5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancerDavid Robinson, Hans Garmo, Lars Holmberg, et al.
Acta Oncologica (Stockholm, Sweden)|February 23, 2013
Population-based study on use of chemotherapy in men with castration resistant prostate cancerIngela Franck Lissbrant, Hans Garmo, Anders Widmark, et al.
Annals of Surgical Oncology|December 2, 2016
The Influence of Preoperative Symptoms on the Death of Patients with Small Intestinal Neuroendocrine TumorsJohn Eriksson, Hans Garmo, Per Hellman, et al.
The Journal of Urology|April 4, 2020
5α-Reductase Inhibitors and Risk of Prostate Cancer DeathTiago Bonde Miranda, Hans Garmo, Par Stattin, et al.
Cancers|March 6, 2021
The Value of Real-World Data in Understanding Prostate Cancer Risk and Improving Clinical Care: Examples from Swedish RegistriesKerri Beckmann, Hans Garmo, Ingela Franck Lissbrant, et al.
European Urology|August 22, 2016
Re: Adi J. Klil-Drori, Hui Yin, Vicky Tagalakis, Armen Aprikian, Laurent Azoulay. Androgen Deprivation Therapy for Prostate Cancer and Risk of Venous Thromboembolism. Eur Urol 2016;70:56-61Mieke Van Hemelrijck, Hans Garmo, Jan Adolfsson, et al.
BJU International|September 11, 2022
Evidence of cancer progression as the cause of death in men with prostate cancer in SwedenAndri Wilberg Orrason, Johan Styrke, Hans Garmo, et al.
Plos One|October 7, 2021
Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemicRolf Gedeborg, Johan Styrke, Stacy Loeb, et al.
Journal of the National Cancer Institute|July 13, 2016
Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based StudyOla Bratt, Linda Drevin, Olof Akre, et al.
Pageof 28

Showing results (11-20 of 275) with videos related to

Sort By:
Pageof 28
The Journal of Urology|June 22, 2016
Cancer Specific Mortality in Men Diagnosed with Prostate Cancer before Age 50 Years: A Nationwide Population Based StudyAndreas Thorstenson, Hans Garmo, Jan Adolfsson, et al.
Cancer Causes & Control : CCC|June 26, 2015
5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancerDavid Robinson, Hans Garmo, Lars Holmberg, et al.
Acta Oncologica (Stockholm, Sweden)|February 23, 2013
Population-based study on use of chemotherapy in men with castration resistant prostate cancerIngela Franck Lissbrant, Hans Garmo, Anders Widmark, et al.
Annals of Surgical Oncology|December 2, 2016
The Influence of Preoperative Symptoms on the Death of Patients with Small Intestinal Neuroendocrine TumorsJohn Eriksson, Hans Garmo, Per Hellman, et al.
The Journal of Urology|April 4, 2020
5α-Reductase Inhibitors and Risk of Prostate Cancer DeathTiago Bonde Miranda, Hans Garmo, Par Stattin, et al.
Cancers|March 6, 2021
The Value of Real-World Data in Understanding Prostate Cancer Risk and Improving Clinical Care: Examples from Swedish RegistriesKerri Beckmann, Hans Garmo, Ingela Franck Lissbrant, et al.
European Urology|August 22, 2016
Re: Adi J. Klil-Drori, Hui Yin, Vicky Tagalakis, Armen Aprikian, Laurent Azoulay. Androgen Deprivation Therapy for Prostate Cancer and Risk of Venous Thromboembolism. Eur Urol 2016;70:56-61Mieke Van Hemelrijck, Hans Garmo, Jan Adolfsson, et al.
BJU International|September 11, 2022
Evidence of cancer progression as the cause of death in men with prostate cancer in SwedenAndri Wilberg Orrason, Johan Styrke, Hans Garmo, et al.
Plos One|October 7, 2021
Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemicRolf Gedeborg, Johan Styrke, Stacy Loeb, et al.
Journal of the National Cancer Institute|July 13, 2016
Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based StudyOla Bratt, Linda Drevin, Olof Akre, et al.
Pageof 28